May 19, 2020
Eiger BioPharmaceuticals Announces FDA Acceptance of NDA for Filing with Priority Review of Zokinvy(TM) (lonafarnib) for Treatment of Progeria and Progeroid Laminopathies
May 07, 2020
Eiger BioPharmaceuticals Reports First Quarter 2020 Financial Results and Provides Business Update
Apr 27, 2020
Eiger BioPharmaceuticals Announces EMA Validation of Lonafarnib MAA for Treatment of Progeria and Progeroid Laminopathies
Apr 01, 2020
Eiger BioPharmaceuticals Provides Update on Clinical Development Activities and Business Operations During COVID-19 Pandemic
Mar 23, 2020
Eiger BioPharmaceuticals Completes Submission of New Drug Application to FDA for Lonafarnib for Treatment of Progeria and Progeroid Laminopathies
Mar 13, 2020
Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update
Jan 07, 2020
Eiger BioPharmaceuticals Appoints Industry Veteran Eldon Mayer as Executive Vice President and Chief Commercial Officer
Jan 06, 2020
Eiger Updates on 2019 Progress and 2020 Milestones Expected
Dec 17, 2019
First-Ever Treatment for Rare, Rapid-Aging Disease Progeria Submitted in New Drug Application to the FDA
Dec 16, 2019
Eiger Initiates Rolling Submission of New Drug Application (NDA) with FDA for Lonafarnib for Treatment of Progeria and Progeroid Laminopathies
Sep 27, 2019
Eiger to Present at Cantor 2019 Global Healthcare Conference
Jun 05, 2019
Eiger Appoints Jeysen Yogaratnam, MB.BCh, BAO, MRCSEd, PhD, MBA, Vice President of Global HDV Clinical Development
May 30, 2019
Eiger BioPharmaceuticals to Present at Jefferies 2019 Global Healthcare Conference
May 17, 2019
Eiger BioPharmaceuticals Announces Transition of Chief Operating Officer and Executive Medical Officer
Apr 30, 2019
Eiger to Present at ChinaBio® Partnering Forum 2019
Mar 26, 2019
Eiger BioPharmaceuticals to Participate in Conferences in April
Mar 20, 2019
Eiger BioPharmaceuticals Management Team to Present and Participate in China Healthcare Investment Conference 2019
Mar 14, 2019
Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update
Dec 19, 2018
Eiger Announces Breakthrough Therapy Designation Granted by FDA for Lonafarnib in Progeria and Progeroid Laminopathies
Dec 18, 2018
Eiger Announces PRIME Designation Granted by European Medicines Agency for Lonafarnib for Treatment of Hepatitis Delta Virus Infection